Cox-2, EGFR, and ERBB-2 expression in cervical intraepithelial neoplasia and cervical cancer using an automated imaging system

International Journal of Gynecological Pathology

Volumn 33, Issue 3, 2014, Pages 225-234

  Fukazawa, Elza M ^a   Baiocchi, Glauco ^a   Soares, Fernando A ^b   Kumagai, Lillian Y ^a   Faloppa, Carlos C ^a   Badiglian Filho, Levon ^a   Coelho, Francisco R G ^a   Gonçalves, Wagner J ^c   Costa, Ronaldo L R ^a   Góes, João C S ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b Department of Pathology Department of Gynecologic Oncology ^*  (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cervical intraepithelial neoplasia; Cyclooxygenase 2; EGFR; ERBB 2; Uterine cervical neoplasm

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; VASCULOTROPIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PTGS2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; AUTOMATION; CANCER STAGING; FEMALE; HUMAN; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; DISEASE COURSE; LABORATORY AUTOMATION; METABOLISM; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PRECANCER; RETROSPECTIVE STUDY; TISSUE MICROARRAY; UTERINE CERVIX TUMOR;

AUTOMATION, LABORATORY; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84898597787     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e318290405a     Document Type: Article

References (66)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base number 10. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr. Accessed December 12, 2010.
2. de Sanjose S, Quint WG, Alemany L, et al. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56.
3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
4. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
5. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004;324:17-27.
6. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-part B: biological agents. Lancet Oncol 2009; 10:321-22.
7. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intra-epithelial neoplasia. JAMA 2001;286:3106-14.
8. Wang D, Dubois N. Eicosanoids and cancer. Nat Rev Cancer 2010;181-93.
9. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
10. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004;102:37-46.
11. Hu G, Liu W, Mendelsohn J, et al. Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst 1997;89:1271-6.
12. Akerman GS, Tolleson WH, Brown KL, et al. Human Papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Cancer Res 2001;61:3837-43.
13. Woodworth CD, Gaiotti D, Michael E, et al. Targeted disruption of the epidermal growth factor receptor inhibits development of papillomas and carcinomas from human papillomavirus-immortalized kerotinocytes. Cancer Res 2000;60:4397-402.
14. Yasmeen A, Hosein AN, Yu Q, et al. A critical role for D-type cyclins in cellular transformation induces by E6/E7 of human papillomavirus type 16 and E6/E7/ErbB-2 cooperation. Cancer Sci 2007;1-5.
15. Narisawa-Saito M, Handa K, Yugawa T, et al. HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes. Oncogene 2007;26:2988-96.
16. Moasser MM. The oncogene HER2: it's signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26:6469-87.
17. Dannenberg AJ, Lippman SM, Mann JR, et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23:254-64.
18. Rocha RM, Miller K, Soares F, et al. Biotin-free systems provide stronger immunohistochemical signal in oestrogen receptor evaluation of breast cancer. J Clin Pathol 2009; 62:699-704.
19. Coutinho-Camillo CM, Lourenço SV, Nishimoto IN, et al. Caspase expression in oral squamous cell carcinoma. Head Neck 2011;33:1191-8.
20. Coutinho-Camillo CM, Lourenço SV, Nishimoto IN, et al. Expression of Bcl-2 family proteins and association with clinicopathological characteristics of oral squamous cell carcinoma. Histopathology 2010;57:304-16.
21. Bauer KD, de la Torre-Bueno J, Diel IJ, et al. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 2000;6:3552-9.
22. Bloom K, Harrington D. Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol 2004;121:620-30.
23. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
24. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
25. Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high-risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002;325:572-8.
26. Kruse AJ, Baak JP, Janssen EA, et al. Low and high risk CIN1 and 2 lesions: prospective value of grade, HPV and Ki67 immunoquantitative variables. J Pathol 2003;199:462-70.
27. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:2229-42.
28. Gray LJ, Herington CS. Molecular markers for the prediction of progression of CIN lesions. Int J Gynecol Pathol 2004;23:95-6.
29. Syrjanen KJ. Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis. Eur J Gynaecol Oncol 2005;26:118-24.
30. INK4A expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 2004;23:354-65.
31. Branca M, Giorgi C, Santini D, et al. Aberrant expression of vascular endothelial growth factor-C (VEGF-C) is related to grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer. J Clin Pathol 2006;59:40-7.
32. Branca M, Giorgi C, Ciotti M, et al. Down-regulation of nucleoside diphosphate (NDP) kinase nm23-H1 expression is unrelated to high-risk human papillomavirus (HPV) but associated with progression of CIN and unfavourable prognosis of cervical cancer. J Clin Pathol 2006;59:1044-51.
33. Branca M, Giorgi C, Ciotti M, et al. Over-expression of topoisomerase IIa is related to the grade of cervical intra-epithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict prognosis in cervical cancer or HPV clearance after cone treatment. Int J Gynecol Pathol 2006;25:383-92.
34. INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001;25:884-91.
35. Kruse AJ, Skaland I, Janssen EA, et al. Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions: role of markers of proliferative activity and differentiation and Rb availability. Int J Gynecol Pathol 2004;23:100-9.
36. Branca M, Ciotti M, Giorgi C, et al. Predicting high-risk human papillomavirus infection, progression of cervical intra-epithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling. Int J Gynecol Pathol 2008;27:265-73.
37. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2 transcription in regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a coexpressor/coactivator exchange. Cancer Res 2007;67:3976-85.
38. Herfs M, Herman L, Hubert P, et al. High Expression of PGE2 enzymatic pathways in cervical (pre) neoplastic and functional consequences for antigen-presenting cells. Cancer Immunol Immunother 2009;58:603-14.
39. Tortora G, Caputo R, Damiano V, et al. Combination of selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase a antisense causes cooperative antitumor and anti-angiogenic effect. Clin Cancer Res 2003;9:1566-72.
40. Moraitis D, Du B, Lorenzo MS, et al. Levels of cyclo-oxygenase-2 are increased in oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 2005;65:664-70.
41. Farley J, Uyehara C, Hashiro G, et al. Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure. Gynecol Oncol 2004;92:596-602.
42. Sarian LO, Derchain SF, Yoshida A, et al. Expression of cyclooxigenase-2 (COX-2) and Ki67 as related to disease severity and HPV detection in squamous lesions of the cervix. Gynecol Oncol 2006;102:537-541.
43. Dursun P, Yuce K, Usubutun A, et al. Cyclooxygenase-2 expression in cervical intraepithelial neoplasia III and squ-amous cell cervical carcinoma, and its correlation with clinic pathologic variables. Int Gynecol Cancer 2007;17:164-73.
44. Kim JY, Lim SJ, Park K, et al. Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecol Oncol 2005;97:337-41.
45. Kim GE, Kim YB, Cho NH, et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res 2004;10:1366-74.
46. Athavale R, Clooney K, O'Hagan J, et al. COX-1 and COX-2 expression in stage I and II invasive cervical carcinoma: relationship to disease relapse and long-term survival. Int J Gynecol Cancer 2006;16:1303-8.
47. Boer WI, Hau CH, Schadewijk A, et al. Expression of epidermal growth factors and their receptors in the bronchial of subjects with chronic obstructive pulmonary disease. Am J Clin Pathol 2006;125:184-92.
48. Maruo T, Yamasaki M, Ladines-Llave CA, et al. Immunohis-tochemical demonstration of elevated expression of epidermal growth factor receptor in neoplastic changes of cervical squamous epithelium. Cancer 1992;69:1182-7.
49. Mathur SP, Mathur RS, Rust PF, et al. Human papilloma virus (HPV)-E6/E7 and epidermal Growth factor receptor (EGF-R) protein levels in cervical cancer and cervical intraepithelial neoplasia (CIN). Am J Reprod Immunol 2001;46:280-287.
50. Kersemaekers AM, Fleuren GJ, Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999;5:577-586.
51. Kristensen GB, Holm R, Abele V, et al. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996; 78:433-40.
52. Boiko IV, Mitchell MF, Hu W, et al. Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an a-difluoromethylornithine chemopreven-tion trial. Clin Cancer Res 1998;4:1383-91.
53. Berchuck A, Rodrigues G, Kamel A, et al. Expression of epidermal growth factor receptor and Her-2/Neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol 1990; 76:381-7.
54. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Mol Cell Biol 2006;7: 131-42.
55. Wever O, Pauwels P, Craene B, et al. Molecular and pathological signatures of epithelial-mesenchymal transition at cancer invasion front. Histochem Cell Biol 2008;130:481-94.
56. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
57. Lee MY, Chou CY, Tang MJ, et al. Epithelial mesenchymal transition in cervical cancer: correlation with tumor progression. Epidermal growth factor receptor overexpression, and snail up-regulation. Clin Cancer Res 2008;14:4743-50.
58. Lippman SM, Gibson N, Subbaramaiah K, et al. Combined targeting of the epidermal growth factor receptor and cyclo-oxygenase-2 pathways. Clin Cancer Res 2005;11:6097-9.
59. Krysan K, Lee JM, Dohadwala M, et al. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol 2008;3:107-10.
60. Jang TJ, Jeon KH, Jung KH. Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition on human colon cancers. Yonsei Med J 2009;50:818-24.
61. Lesnikova I, Lidang M, Hamilton-Dutoit S, et al. HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. APMIS 2009;117:737-45.
62. Oka K, Nakano T, Arai T. c-erbB-2 Oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 1994;73:664-71.
63. Ngan HY, Cheung AN, Liu SS, et al. Abnormal expression of epidermal growth factor receptor an erbB-2 in squamous cell carcinoma of the cervix: correlation with human papillomavi-rus and prognosis. Tumour Biol 2001;22:176-83.
64. Bellone S, Palmieri M, Gokden M, et al. Selection of HER-2/neu-positive tumor cell in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecol Oncol 2003;91:231-40.
65. Zlobec I, Terracciano L, Jass JR, et al. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch 2007;451: 763-9.
66. Cregger M, Berger AJ, Rimm DL. Immunohistochemical and quantitative analysis of protein expression. Arch Pathol Lab Med 2006;130:1026-30.